1. Home
  2. CC vs RAPP Comparison

CC vs RAPP Comparison

Compare CC & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chemours Company (The)

CC

Chemours Company (The)

HOLD

Current Price

$14.33

Market Cap

2.3B

Sector

Industrials

ML Signal

HOLD

Logo Rapport Therapeutics Inc.

RAPP

Rapport Therapeutics Inc.

HOLD

Current Price

$40.75

Market Cap

2.3B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CC
RAPP
Founded
2014
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.3B
IPO Year
2014
2024

Fundamental Metrics

Financial Performance
Metric
CC
RAPP
Price
$14.33
$40.75
Analyst Decision
Buy
Strong Buy
Analyst Count
9
6
Target Price
$20.11
$48.50
AVG Volume (30 Days)
1.6M
263.9K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
1.33%
N/A
EPS Growth
N/A
24.34
EPS
N/A
N/A
Revenue
$6,638,000,000.00
N/A
Revenue This Year
$6.15
N/A
Revenue Next Year
$5.95
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.36
N/A
52 Week Low
$10.44
$23.75
52 Week High
$28.67
$52.93

Technical Indicators

Market Signals
Indicator
CC
RAPP
Relative Strength Index (RSI) 36.79 33.60
Support Level $11.55 $38.95
Resistance Level $16.37 $43.99
Average True Range (ATR) 0.51 1.96
MACD -0.04 -0.88
Stochastic Oscillator 14.02 3.81

Price Performance

Historical Comparison
CC
RAPP

About CC Chemours Company (The)

The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, paints and coatings, plastics, transportation, semiconductor, and others. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Share on Social Networks: